logo

Zogenix, Inc. (ZGNX)



Trade ZGNX now with
  Date
  Headline
7/12/2018 7:05:15 AM Zogenix Announces Positive Top-line Results From Second Pivotal Phase 3 Clinical Trial Of ZX008 In Dravet Syndrome
6/1/2018 4:38:00 PM Zogenix Reports Granting Of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
4/25/2018 8:14:05 AM Zogeni Presents New Safety Data From First Pivotal Phase 3 Clinical Trial Of ZX008 In Dravet Syndrome
2/6/2018 8:06:57 AM Zogenix Reports Receipt Of FDA Breakthrough Therapy Designation For ZX008 In Dravet Syndrome
12/1/2017 2:51:57 AM In The Spotlight: Zogenix
11/29/2017 8:06:19 AM Zogenix Initiates Phase 3 Trial For ZX008 In Lennox-Gastaut Syndrome
11/21/2017 8:14:47 AM Zogenix To Present New Data From Phase 3 Trial Of ZX008 In Dravet Syndrome (Study 1)
10/2/2017 8:35:12 PM Zogenix Prices Underwritten Public Offering Of 6.70 Mln Shares At $37.50/shr
10/2/2017 6:54:57 AM Zogenix Proposes 4.3 Mln Shares In An Underwritten Public Offering